Company profile: Zynerba Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of innovative transdermal cannabinoid treatments for neuropsychiatric disorders, developing proprietary dermal solutions and therapeutic candidates using modern drug delivery technology. Offers Zygel (ZYN002 cannabidiol gel) for Fragile X syndrome and 22q11.2 deletion syndrome, and conducts clinical trials across various countries to assess its safety and efficacy.
Products and services
- Clinical Trials for Zygel: Zynerba conducts regulatory-pathway aligned clinical studies across various countries evaluating safety and efficacy of Zygel in patients with neuropsychiatric conditions
- Proprietary Transdermal Cannabinoid Technology Platform: Zynerba architects proprietary transdermal technologies using modern dermal drug delivery to develop therapies for high unmet neuropsychiatric needs, underpinning two therapeutic candidates
- Zygel (ZYN002 Cannabidiol Gel): A pharmaceutically-manufactured transdermal cannabidiol gel engineered to treat neuropsychiatric conditions, specifically Fragile X syndrome (FXS) and 22q11.2 deletion syndrome.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Zynerba Pharmaceuticals
Nanoco Technologies
HQ: United Kingdom
Website
- Description: Provider of cadmium-free quantum dots and other nanomaterials for applications including LCD displays, lighting, solar cells, and bio-imaging. Offers CFQD® for display technologies, infra-red sensing nanomaterials for IoT, and Molecular Seeding Technology for precise quantum dot doping, enabling quantum memory and quantum repeater applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanoco Technologies company profile →
Kontem
HQ: Germany
Website
- Description: Provider of phase contrast systems for transmission electron microscopes that significantly improve image quality, especially for biological applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kontem company profile →
Topas Therapeutics
HQ: Germany
Website
- Description: Provider of nanoparticle-based therapeutics and the Topas Particle Conjugates platform to induce antigen-specific immune tolerance by harnessing the liver’s tolerogenic power, targeting autoimmune and antigen-driven diseases (including allergies and anti-drug antibodies), with clinical candidates TPM203 (Phase 1) for pemphigus vulgaris and TPM502 (Phase 2) for celiac disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Topas Therapeutics company profile →
Actnano
HQ: United States
Website
- Description: Provider of nanotechnology-based smart coatings that protect electronics and surfaces from water and harsh environmental conditions. Offerings include PFAS- and fluorine-free Advanced nanoGUARD conformal coating for full PCBA protection against moisture, humidity, condensation, salt and sweat, and durable anti-fog coatings. Serves automotive (including ADAS), consumer electronics, medical devices, solar and industrial electronics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Actnano company profile →
Cambridge Graphene
HQ: United Kingdom
Website
- Description: Provider of graphene and 2D materials technology for licensing to manufacturers, offering graphene inks for inkjet and screen printing for coatings, printed electronics, sensors and energy storage; custom ink formulations; graphene-enhanced composite development; supercapacitors and batteries; Graphinks printable inks/coatings with high electrical and thermal conductivity, fire retardation and UV protection; and hBN dielectric inks.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cambridge Graphene company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Zynerba Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Zynerba Pharmaceuticals
2.2 - Growth funds investing in similar companies to Zynerba Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Zynerba Pharmaceuticals
4.2 - Public trading comparable groups for Zynerba Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →